Navigate the Astex Pharma ASTX Research Pages
- Introduction (background, summary, links, valuation, financials, outlook, upcoming catalysts)
- Supergen-Astex merger (details on transformative transaction in 2011)
- DACOGEN (aka decitabine, marketed product for myelodysplastic syndrome MDS by Eisai and JNJ)
- AT13387 (HSP90 inhibitor for cancer)
- SGI-110 (follow-on to Dacogen for MDS and AML)
- Amuvatinib (aka MP470 in development for small-cell lung cancer SCLC)
- AT7519 (CDK inhibitor for multiple myeloma)
- Fragment-based Drug Discovery Collaborations (via Astex Ltd side of merger)
- Pipeline (other assets in development)
- Montigen (proposed spin-out transaction info and assets)
Monitgen
- This is the name of the company that Supergen SUPG (now Astex Pharma ASTX - click for my research page) bought in 2006
- ASTX has announced that they will be spinning off some of the assets from the Supergen-Astex merger, along with certain assets from Ascalon International to form a new company to be called Montigen.
- Click here for a business plan summary outline with more details about Ascalon assets, plans, timelines, and funding requirements.
- July 2012 Update - the spinout plan has been abandoned (no surprise after the lengthy delay) - ASTX sells the CLIMB discovery assets including PIM kinase program to Tolero Pharma of Salt Lake City - for 6% equity. This includes PIM kinase and other discovery programs, but not AT7519 or AT9283. (via 2q-2012 earnings conference call)
Links
Click here for ASTX home page - but no mention of Montigen yet
8/21/2011 SUPG 2q2011 earnings conference call (first mention of spinout) - click here for my notes.
9/12/2011 Rodman and Renshaw webcast by ASTX - click here for my notes.
9/13/2011 Rodman and Renshaw webcast by Monitgen - click here for my notes.
9/21/2011 UBS webcast by ASTX - click here for notes.
9/27/2011 Jefferies webcast by ASTX - click here for notes.
10/21/2011 BioCentury webcast by ASTX - click here for notes.
8/21/2011 SUPG 2q2011 earnings conference call (first mention of spinout) - click here for my notes.
9/12/2011 Rodman and Renshaw webcast by ASTX - click here for my notes.
9/13/2011 Rodman and Renshaw webcast by Monitgen - click here for my notes.
9/21/2011 UBS webcast by ASTX - click here for notes.
9/27/2011 Jefferies webcast by ASTX - click here for notes.
10/21/2011 BioCentury webcast by ASTX - click here for notes.
Navigate through the slide deck before to learn more about the proposed company and its assets. These slides are from the presentation by Monitgen's management team at the Rodman and Renshaw conference in September 2011.
Discovery Programs - CLIMB platform
- AXL Kinase. 2010 10k: "thirteen patent applications, having projected expiration dates ranging from April 11, 2028 to February 8, 2030, pending in the jurisdictions of the U.S., the EPO, Australia, Canada, China, Japan, Korea, New Zealand, and Taiwan."
- PIM Kinase backups
- Cancer Metabolism
- Tyrosine Kinase inhibitor programs
- January 2011- collaborating with Proteros for assistance in identifying lead compounds against a target of interest - click here for press release (unsure of status of this deal following merger with Astex)